Annual report pursuant to Section 13 and 15(d)

Revenue Recognition - Disaggregation of Revenue (Details)

v3.20.4
Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Disaggregation of Revenue [Line Items]      
Total revenues $ 69,056 $ 68,458 $ 60,594
Americas      
Disaggregation of Revenue [Line Items]      
Total revenues 24,352 13,039 15,370
EMEA      
Disaggregation of Revenue [Line Items]      
Total revenues 19,257 37,133 22,361
APAC      
Disaggregation of Revenue [Line Items]      
Total revenues 25,447 18,286 22,863
Product revenue      
Disaggregation of Revenue [Line Items]      
Total revenues 30,220 29,465 25,590
Research and development revenue      
Disaggregation of Revenue [Line Items]      
Total revenues 38,836 38,993 35,004
Performance Enzymes      
Disaggregation of Revenue [Line Items]      
Total revenues 48,106 58,156 47,073
Performance Enzymes | Americas      
Disaggregation of Revenue [Line Items]      
Total revenues 11,111 13,039 15,332
Performance Enzymes | EMEA      
Disaggregation of Revenue [Line Items]      
Total revenues 11,548 26,831 8,878
Performance Enzymes | APAC      
Disaggregation of Revenue [Line Items]      
Total revenues 25,447 18,286 22,863
Performance Enzymes | Product revenue      
Disaggregation of Revenue [Line Items]      
Total revenues 30,220 29,465 25,590
Performance Enzymes | Research and development revenue      
Disaggregation of Revenue [Line Items]      
Total revenues 17,886 28,691 21,483
Novel Biotherapeutics      
Disaggregation of Revenue [Line Items]      
Total revenues 20,950 10,302 13,521
Novel Biotherapeutics | Americas      
Disaggregation of Revenue [Line Items]      
Total revenues 13,241 0 38
Novel Biotherapeutics | EMEA      
Disaggregation of Revenue [Line Items]      
Total revenues 7,709 10,302 13,483
Novel Biotherapeutics | APAC      
Disaggregation of Revenue [Line Items]      
Total revenues 0 0 0
Novel Biotherapeutics | Product revenue      
Disaggregation of Revenue [Line Items]      
Total revenues 0 0 0
Novel Biotherapeutics | Research and development revenue      
Disaggregation of Revenue [Line Items]      
Total revenues $ 20,950 $ 10,302 $ 13,521